Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.

@article{Pascucci2014PaclitaxelII,
  title={Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.},
  author={Luisa Pascucci and Valentina Cocc{\`e} and Arianna Bonomi and Diletta Ami and Piero Ceccarelli and Emilio Ciusani and Lucia Vigan{\`o} and Alberta Locatelli and Francesca Sisto and Silvia Maria Doglia and Eugenio Agostino Parati and Maria Ester Bernardo and Maurizio Muraca and Giulio Alessandri and Gianpietro Bondiolotti and Augusto Pessina},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2014},
  volume={192},
  pages={262-70}
}
Mesenchymal stromal cells (MSCs) have been proposed for delivering anticancer agents because of their ability to home in on tumor microenvironment. We found that MSCs can acquire strong anti-tumor activity after priming with Paclitaxel (PTX) through their capacity to uptake and then release the drug. Because MSCs secrete a high amount of membrane microvesicles (MVs), we here investigated the role of MVs in the releasing mechanism of PTX. The murine SR4987 line was used as MSC model. The release… CONTINUE READING